MedTrace Logo

Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET

NCT01185119 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2011-03-22

No results posted yet for this study

Summary

10 healthy men will be PET-scanned (CNS) twice in random order with infusions of placebo or Native GLP-1 during hyperglycemic clamp to uncover the metabolic effects of GLP-1 in perspectives of intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in blood sugar when infusing native GLP-1.

Conditions

  • Healthy

Interventions

DRUG

native glp-1 (7-36)

During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Birgitte Brock, asso.prof. · University of Aarhus, Dept. of Pharmacology

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-12-31
Completion
2011-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01185119 on ClinicalTrials.gov